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Background: Asthma is a chronic disease that is characterized by airway hyperresponsiveness and airway
remodeling. The underlying mechanisms that mediate the pathological processes are not fully understood. Abl is a
non-receptor protein tyrosine kinase that has a role in the regulation of smooth muscle contraction and smooth
muscle cell proliferation in vitro. The role of Abl in airway hyperresponsiveness and airway remodeling in vivo is
largely unknown.
Methods: To evaluate the role of Abl in asthma pathology, we assessed the expression of Abl in airway tissues
from the ovalbumin sensitized and challenged mouse model, and human asthmatic airway smooth muscle cells. In
addition, we generated conditional knockout mice in which Abl expression in smooth muscle was disrupted, and
then evaluated the effects of Abl conditional knockout on airway resistance, smooth muscle mass, cell proliferation,
IL-13 and CCL2 in the mouse model of asthma. Furthermore, we determined the effects of the Abl pharmacological
inhibitors imatinib and GNF-5 on these processes in the animal model of asthma.
Results: The expression of Abl was upregulated in airway tissues of the animal model of asthma and in airway
smooth muscle cells of patients with severe asthma. Conditional knockout of Abl attenuated airway resistance,
smooth muscle mass and staining of proliferating cell nuclear antigen in the airway of mice sensitized and
challenged with ovalbumin. Interestingly, conditional knockout of Abl did not affect the levels of IL-13 and CCL2 in
bronchoalveolar lavage fluid of animals treated with ovalbumin. However, treatment with imatinib and GNF-5
inhibited the ovalbumin-induced increase in IL-13 and CCL2 as well as airway resistance and smooth muscle
growth in animals.
Conclusions: These results suggest that the altered expression of Abl in airway smooth muscle may play a critical
role in the development of airway hyperresponsiveness and airway remodeling in asthma. Our findings support the
concept that Abl may be a novel target for the development of new therapy to treat asthma.
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Asthma is a chronic airway disease characterized by air-
way hyperresponsiveness (AHR) and airway remodeling,
which lead to impaired respiratory air flow in patients
with asthma. However, the underlying mechanisms for
the pathological processes are not fully understood.
AHR is largely attributed to hyperreactivity of airway
smooth muscle [1]. The contractile properties of human
asthmatic airway smooth muscle cells are distinctive
from normal human airway smooth muscle cells [2,3].* Correspondence: tangd@mail.amc.edu
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stated.In addition, the hyperreactivity of airway smooth muscle
tissues occurs in animal models of asthma [4,5]. Further-
more, increased airway smooth muscle cell proliferation
contributes to the progression of airway remodeling in
asthma [6,7]. Airway smooth muscle hyperplasia may
facilitate the thickening of the bronchial wall and pro-
mote AHR to a variety of stimuli [7,8].
Abl (Abelson tyrosine kinase, c-Abl) is a non-receptor
tyrosine kinase that participates in the regulation of a range
of cellular functions including migration and adhesion of
nonmuscle cells [9,10]. Recent studies have implicated Abl
in the regulation of vascular smooth muscle contraction
in vitro. Contractile activation induces Abl phosphorylation,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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Knockdown of Abl attenuates smooth muscle force deve-
lopment in response to contractile activation [11-13]. More-
over, Abl has been implicated in regulating smooth muscle
cell proliferation. Activation of Abl occurs in smooth muscle
cells in response to stimulation with growth factors.
Silencing of Abl inhibits smooth muscle cell proliferation
induced by growth factors [14,15]. Nevertheless, the role
of Abl in asthma pathology in vivo is largely unknown.
In this study, we generated smooth muscle-specific
conditional knockout mice, and determined whether
smooth muscle-specific knockout of Abl affects AHR
and airway remodeling in a mouse model of chronic
asthma. Our results suggest that the altered expression
of Abl in airway smooth muscle is critical for the deve-
lopment of AHR and airway remodeling.
Methods
Animals and measurement of airway resistance
Abl-lox mice were a gift of Dr. Koleske of Yale University
[16]. SM22cre mice were purchased from The Jackson
Laboratory. Abl-lox mice (genetic background, 129/Svj)
were crossed with SM22cre mice on C57BL/6 back-
ground. These mice express Cre recombinase under
control of a smooth muscle-specific SM22 promoter.
As a consequence, this loxP flanked exon 5 of the abl
gene was excised in smooth muscle cells (Figure 1A).
The sequences of primers used to identify the genotype
were: Primer 1, 5’-CTGTACGTGTCCTCCGAGAG-3’;Figure 1 Targeting of the abl gene in smooth muscle cells. (A) SM22-C
region. The abl locus containing a floxed version of the Exon5 of abl and t
Numbered arrows represent PCR primers. (B) Ethidium bromide-stained ag
mouse strains. PCR with primers 3 and 5 demonstrate selective deletion of
Each lane represents tail DNA samples isolated from an individual mouse o
from Abl-lox and Ablsm−/− mice were analyzed by immunoblotting. Knockou
Representative blots from three separate experiments are shown.Primer 2, 5’-CTTCAAGGTCTTCACGGCCA-3’; Primer
3, 5’-GATGTCTCTACAGGGTTAAGATTAAGAGCA-3’;
Primer 4, 5’-TGTGCATAGCAGGAAGTCCTCCAGAG-
3’; Primer 5, 5’-AGTTAACACACCTCCAGAGTGAGTG
CCCT-3’.
Age- and sex-matched Abl-lox (control) mice and
Ablsm−/− (smooth muscle specific knockout of abl gene)
mice (6–7 weeks old) were sensitized by intraperitoneal
injection of sterile LPS-free ovalbumin (OVA) (Pierce)
or phosphate buffered saline (PBS, control) for three
weeks, and challenged with intranasal instillations of
OVA or PBS twice a week for eight weeks using pre-
viously-described protocols [17] with minor modification
(Figure 2). To measure airway resistance, mice were
anesthetized with an intraperitoneal injection of pen-
tobarbital sodium, tracheotomized, and connected to
the FlexiVent system (SCIREQ, Montreal, Canada) on
Day 77. Mice were mechanically ventilated at 150
breaths/minute with a tidal volume of 10 ml/kg and a
positive end-expiratory pressure (PEEP) of 3.35 cm
H2O. Following baseline measurements, mice were
challenged with methacholine (MCh) aerosol for 10
seconds at different doses. Airway resistance was mea-
sured for each mouse after inhalation of the aerosol.
Dose–response curve was then determined. This study
was approved by the Institutional Committee of Animal
Care and Usage of Albany Medical College.
To assess the effects of inhibitors, BALB/c mice (6–7
weeks old) were purchased from The Jackson Laboratory.re construct possesses a SM22 promoter (PSM22) and a Cre coding
he predicted product of Cre-mediated recombination are also shown.
arose gel of PCR products amplified from mouse tails of indicated
DNA between loxP sites in the presence of Cre recombinase in vivo.
f the indicated genotype. (C) Extracts of airway smooth muscle cells
t of the Abl protein is verified in airway smooth muscle.
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Figure 2 Sensitization, challenge and treatment protocol for the animal model of chronic asthma. I.P., intraperitoneal injection. I.N.,
intranasal instillation.
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above. In addition, animals were intranasally instilled with
10 mg/kg GNF-5 or imatinib, or PBS 1 h before OVA
instillation and 5 h after OVA instillation for last three
weeks (Figure 2). Airway resistance in these mice was
then assessed on Day 77.
Assessment of tracheal ring contraction
Mice were euthanized by injection of pentobarbital (140
mg/kg). A segment of tracheas (4–5 mm in length) was
immediately removed and placed in physiological saline
solution (PSS) containing 110 mM NaCl, 3.4 mM KCl, 2.4
mM CaCl2, 0.8 mM MgSO4, 25.8 mM NaHCO3, 1.2 mM
KH2PO4, and 5.6 mM glucose. The solution was aerated
with 95%O2-5%CO2 to maintain a pH of 7.4. Two stainless
steel wires were passed through the lumen of tracheal
rings. One of the wires was connected to the bottom of
organ baths and the other was attached to a Grass force
transducer that had been connected to a computer with
A/D converter (Grass). Tracheal segments were then
placed in PSS at 37°C. Passive tension with 0.5 g was ap-
plied to each segment for 60 min. Contractile force in
response to various treatments was then measured.
Cell culture
Human airway smooth muscle (HASM) cells were
prepared from human bronchi and adjacent tracheas
obtained from the International Institute for Advanced
Medicine [15]. Human tissues were non-transplantable
and consented for research. This study was approved by
the Albany Medical College Committee on Research
Involving Human Subjects. Briefly, muscle tissues were
incubated for 20 min with dissociation solution [130 mM
NaCl, 5 mM KCl, 1.0 mM CaCl2, 1.0 mM MgCl2, 10 mM
Hepes, 0.25 mM EDTA, 10 mM D-glucose, 10 mM
taurine, pH 7, 4.5 mg collagenase (type I), 10 mg papain
(type IV), 1 mg/ml BSA and 1 mM dithiothreitol]. Allenzymes were purchased from Sigma-Aldrich. The tissues
were then washed with Hepes-buffered saline solution
(composition in mM: 10 Hepes, 130 NaCl, 5 KCl, 10 glu-
cose, 1 CaCl2, 1 MgCl2, 0.25 EDTA, 10 taurine, pH 7).
The cell suspension was mixed with Ham’s F12 medium
supplemented with 10% (v/v) fetal bovine serum (FBS)
and antibiotics (100 units/ml penicillin, 100 μg/ml strepto-
mycin). Cells were cultured at 37°C in the presence of 5%
CO2 in the same medium. The medium was changed
every 3–4 days until cells reached confluence, and conflu-
ent cells were passaged with trypsin/EDTA solution
[15,18,19]. Smooth muscle cells within passage 5 were
used for the studies.
Immunoblot analysis
Cells were lysed in SDS sample buffer composed of 1.5%
dithiothreitol, 2% SDS, 80 mM Tris–HCl (pH 6.8), 10%
glycerol and 0.01% bromophenol blue. The lysates were
boiled in the buffer for 5 min and separated by SDS-PAGE.
Proteins were transferred to a nitrocellulose membrane.
The membrane was blocked with bovine serum albumin or
milk for 1 h and probed with use of primary antibody
followed by horseradish peroxidase-conjugated secondary
antibody (Fisher Scientific). Proteins were visualized by
enhanced chemiluminescence (Fisher Scientific) using the
LAS-4000 Fuji Image System. Abl antibody was purchased
from BD Biosciences and Santa Cruz Biotechnology.
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) anti-
body was purchased from Fitzgerald (Acton, MA). The levels
of proteins were quantified by scanning densitometry of
immunoblots (Fuji Multigauge Software). The luminescent
signals from all immunoblots were within the linear range.
Immunohistochemistry
Mouse lungs were placed in frozen tissue-embedding
medium (Neg 52, Richard-Allen Scientific) and cryo-
sectioned using Cryostats (Richard-Allen Scientific).
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dehyde, and were then washed three times in PBS buffer
followed by permeabilization with 0.2% Triton X-100
dissolved in PBS for 5 min. These tissues were incubated
with α-smooth muscle actin antibody (Sigma) or proli-
ferating cell nuclear antigen (PCNA) antibody (Thermo
Scientific) followed by appropriate secondary antibody
conjugated to Alexa-488 or Alex-543 (Molecular Probes/
Life Technologies). The sections were also counter-
stained with 4',6-diamidino-2-phenylindole to visualize
the nucleus. The samples were viewed and digitally cap-
tured using a Leica microscope system (MDI 6000). All
immunohistochemical measurements were performed by
using the NIH ImageJ software.
Analysis of airway inflammation
Lungs from sacrificed mice were lavaged three times
with 1 mL sterile Hanks balanced salt solution (HBSS)
containing 3 mM EDTA. Bronchoalveolar lavage fluid
(BALF) was collected after centrifugation and, the super-
natant was removed and frozen at −80°C for cytokine/
chemokine measurements (See below). The cell pellet
was resuspended in HBSS, and total number of inflam-
matory cells in the BALF was counted by using a he-
mocytometer. Differential cell counts (macrophages,
neutrophils, lymphocytes, and eosinophils) were perfor-
med by counting 100 cells from cytospin preparations
stained with DiffQuick stain. The levels of IL-13 and CCL2
in the BALF were determined using ELISA kits (R&D
systems) according to the manufacturer’s instructions.
Statistical analysis
All statistical analysis was performed using Prism 4 soft-
ware (GraphPad Software, San Diego, CA). Comparison
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Figure 3 Abl is required for airway smooth muscle contraction. (A) Tr
with difference concentration of acetylcholine (ACh). Dose–response of the
maximal force of tracheal rings from Abl-lox mice. Values are mean ± SE (n
lox at corresponding doses (P < 0.01). (B) Tracheal rings of Abl-lox mice wer
μM, 10 min). ACh dose–response of tissues was then determined. Pretreatm
in vitro (n = 15–18, * P < 0.01). (C) Tracheal rings of Abl-lox mice were preco
GNF-5 were then imposed to assess the relaxation response. Treatment wit
segments precontracted by ACh (n = 17–19).analysis of variance followed by Tukey’s multiple compari-
son test. Differences between two groups were analyzed
by Student-Newman-Keuls test or Dunn's method. Values
of n refer to the number of experiments used to obtain
each value. P < 0.05 was considered to be significant.
Results
Abl is required for airway smooth muscle contraction
Our previous studies demonstrate that Abl regulates vas-
cular smooth muscle contraction [11-13]. To determine
the role of Abl in airway smooth muscle, we generated
SM22creAbl-lox mice, a mouse model with smooth muscle
cell–specific disruption of the abl gene (Figure 1A). Geno-
typing and immunoblot analysis verified knockout of Abl
in airway smooth muscle (Figure 1B and C). Previous
studies by others demonstrate that SM22 is expressed in
airway smooth muscle tissues [20-22], which suggests that
SM22 promoter is functional in airway smooth muscle.
Our results are consistent with these studies.
Contractile responses of mouse tracheal rings to ACh
stimulation were compared between Ablsm−/− (smooth
muscle knockout of Abl) mice and Abl-lox (control)
mice. As shown in Figure 3A, contractile responses of
mouse tracheal rings to ACh were lower in Ablsm−/−
mice than in Abl-lox mice, which was dose-dependent.
We also evaluated acute effects of the Abl pharmaco-
logical inhibitors imatinib (Gleevec, STI-571) [11,23]
and GNF-5 [24] on airway smooth muscle contraction.
Treatment of mouse tracheal rings with imatinib signifi-
cantly attenuated force development induced by ACh
(Figure 3B). Likewise, GNF-5 had inhibitory effects on
contraction of tracheal segments with slightly stronger
potency (Figure 3B). Furthermore, treatment with ima-
tinib or GNF-5 induced relaxation of tracheal rings
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acheal rings of Ablsm−/− mice and Abl-lox (control) mice were treated
se rings was then evaluated. Contractile force is normalized to
= 9–10). * Significantly lower active force in Ablsm−/− mice than in Abl-
e pretreated with or without the Abl inhibitors imatinib or GNF-5 (10
ent with imatinib or GNF-5 attenuated ACh-induced contraction
ntracted with 100 μM ACh. Different concentrations of imatinib or
h the pharmacological inhibitors induced relaxation of tracheal
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smooth muscle
We evaluated the expression of Abl in airway tissues of
OVA-sensitized and challenged mice, a well-recognized
animal model mimicking allergen-induced asthma in
humans [17]. As shown in Figure 4A, the amount of Abl
was elevated in airway tissues of OVA-treated mice com-
pared to naïve animals. However, the levels of GAPDH
were similar in OVA-treated mice and naïve mice. The
ratio of Abl/GAPDH in airway tissues was higher in
OVA-treated mice than in naïve mice (Figure 4B). To
validate this finding in human asthma, we assessed Abl
expression in HASM cells from normal subjects and
patients with severe asthma. The level of Abl was
higher in asthmatic cells than in normal cells. The ra-
tios of Abl/GAPDH in asthmatic cells were significantly
higher as compared to normal cells (Figure 4A and B).
Conditional knockout of Abl in smooth muscle attenuates
OVA-sensitized airway resistance and contraction of
tracheal rings
We used a chronic asthma animal model [17] to determine
whether Abl in smooth muscle is involved in AHR. Briefly,
Abl-lox and Ablsm−/− mice were sensitized by OVA for three
weeks and challenged by OVA for eight weeks (Figure 2).
Airway resistance in response to methacholine (MCh) in-
halation was measured using the FlexiVent system. OVA
sensitization and challenge induced a higher response to
MCh inhalation in Abl-lox mice as compared to Abl-lox mice
treated with PBS. However, airway resistance induced by
MCh was lower in Ablsm−/− mice sensitized and challenged
by OVA than in Abl-lox mice treated with OVA. The airway
resistance was also lower in naïve Ablsm−/− mice than in
naïve Abl-lox mice (Figure 5A).
We also assessed the effects of Abl knockout on airway
smooth muscle hyperreactivity in vitro. Contractile force in
isolated tracheal rings from OVA-treated Abl-lox mice wasA
Figure 4 The expression of Abl is higher in asthmatic airways tissues/
ovalbumin (OVA)-sensitized and challenged mice and human airway smoo
cell extracts were probed with use of antibodies against Abl and GAPDH. 1
and challenged mice; 3, normal HASM cell extracts; 4, asthmatic HASM cell
OVA-treated animals or asthmatic HASM cells are normalized to correspondgreater compared to naïve Abl-lox mice. However, active
force of isolated tracheal rings from OVA-treated Ablsm−/−
mice was reduced compared to OVA-treated Abl-lox mice.
Contractile response of tracheal rings from naïve Ablsm−/−
mice was also lower compared to naïve Abl-lox mice
(Figure 5B).
Pharmacological inhibition of Abl diminishes AHR
and smooth muscle hyperreactivity
We also evaluated the effects of the Abl inhibitors
imatinib and GNF-5 on AHR in asthmatic animals. The
OVA sensitization and challenge increased airway resist-
ance in BALB/c mice as compared to BALB/c mice
treated with PBS (Figure 6A). In contrast, the OVA-
induced increase in airway resistance was reduced in the
animals treated with imatinib or GNF-5 (Figure 6A). In
addition, treatment with imatinib or GNF-5 inhibited the
ACh-induced contraction in isolated mouse tracheal rings
of OVA-sensitized and challenged mice (Figure 6B).
We noticed that airway resistance in response to MCh
inhalation was slightly higher in BALB/c mice than in Abl-lox
mice sensitized and challenged by OVA (Figure 5A and
Figure 6A). This is not surprising because BALB/c mouse
strain is known to have skewed Th2 response compared
to other mouse strains [25,26].
Conditional knockout of Abl inhibits airway smooth
muscle growth in the animal model of asthma
To determine the role of Abl in the remodeling of air-
way smooth muscle, we assessed whether conditional
knockout of Abl in smooth muscle affects the allergen-
induced airway smooth muscle mass by determining the
area of α-smooth muscle actin (a smooth muscle
marker) staining in the airways of Abl-lox and Ablsm−/−
mice sensitized and challenged with OVA.
The area of α-smooth muscle actin staining in the air-




























cells. (A) The upregulation of Abl expression in the airways of
th muscle (HASM) cells of patients with severe asthma. Blots of tissue/
, tracheal extracts of naïve mice; 2, tracheal extracts of OVA-sensitized
extracts. (B) For quantification analysis, Abl/GAPDH ratios in



























Figure 5 Abl knockout attenuates airway resistance and contraction of tracheal rings in the animal model of asthma. (A) Abl-lox and
Ablsm−/− mice were sensitized and challenged by OVA. Airway resistance (RAW) in these mice was evaluated using the FlexiVent system. RAW in
Abl-lox mice treated with OVA was higher than in Abl-lox mice treated with PBS, verifying the development of AHR in the mouse model. RAW in
Ablsm−/− mice treated with OVA was reduced compared to Abl-lox mice treated with OVA (n = 10–14, *P < 0.05). (B) The contractile response of
tracheal rings from these mice was determined by using an in vitro organ bath system. Contractile force is normalized to maximal force of rings
from OVA-treated Abl-lox mice. Contractile force of OVA-sensitized and challenged Abl-lox mice was increased as compared to naïve Abl-lox mice.
OVA-induced airway smooth muscle contraction was reduced in Ablsm−/− mice (n = 10–14, *P < 0.05).
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immunofluorescent analysis. In contrast, the area of
actin staining in the airways of Ablsm−/− mice treated
with OVA was reduced as compared to Abl-lox mice
treated with OVA (Figure 7A & B). These results suggest
that conditional knockout of Abl is able to attenuate the
allergen-induced increase in airway smooth muscle
mass. In addition, the fluorescent intensity of α-smooth
muscle actin staining was higher in Abl-lox mice treated
with OVA compared to naïve Abl-lox mice, suggesting
higher α-smooth muscle actin expression in the remo-
deled airway in asthmatic models [6]. Furthermore, we
determined the effects of imatinib or GNF-5 on airway












Figure 6 Effects of imatinib and GNF-5 on airway resistance and cont
challenged mice. (A) BALB/c mice were sensitized and challenged with O
in these mice was then measured. Intranasal instillation of imatinib and GN
*Significantly lower airway resistance in animals treated with imatinib or GN
(B) Treatment with imatinib and GNF-5 attenuated the OVA-sensitized trac
force of rings from OVA- and vehicle-treated mice. *Significantly lower trac
compared to vehicle-treated animals (P < 0.05, n = 7–8).attenuated an increase in airway smooth muscle mass
in BALB/c mice sensitized and challenged by OVA
(Figure 7B).
We also evaluated whether the knockout of Abl influ-
ences allergen-induced airway smooth muscle cell proli-
feration. Proliferating cell nuclear antigen (PCNA) is a
critical protein that is expressed by proliferating cells in
S phase of the cell cycle. Thus, it has been widely used
as a marker of cell proliferation in the airways [8,27].
The fluorescent intensity of PCNA colocalized with
α-smooth muscle actin was greater in the airways of
Abl-lox mice treated with OVA compared with Abl-lox
mice treated with PBS. However, the intensity of PCNA
costained with actin in the airways of Ablsm−/− miceractile response of tracheal rings from OVA-sensitized and
VA in the presence of imatinib, GNF-5 or vehicle (V). Airway resistance
F-5 inhibited RAW in mice sensitized and challenged by OVA.
F-5 compared to animals treated with vehicle (P < 0.05, n = 7–8).
heal contraction in vitro. Contractile force is normalized to maximal



















































































Figure 7 Abl knockout inhibits airway remodeling in the animal model of asthma. (A) Representative images illustrating the effects of Abl
knockout on α-actin and PCNA staining. Abl-lox and Ablsm−/− mice were sensitized and challenged with OVA. Lung sections of the mice were
immunostained for α-actin (red) and PCNA (green). The sections were also counterstained with use of 4',6-diamidino-2-phenylindole to visualize
the nucleus (blue). (B) Actin positive area in Ablsm−/− mice treated with OVA was lower compared to Abl-lox mice exposed to OVA (n = 6–7,
*P < 0.05). Treatment with imatinib or GNF-5 inhibited the OVA-induced increase in actin positive area from BALB/c mice (n = 6–7, *P < 0.05). C,
control animals. (C) Fluorescent intensity of PCNA colocalized with actin in the airways in Ablsm−/− mice treated with OVA was lower than that in
Abl-lox mice exposed to OVA (n= 6–7, *P < 0.05). Treatment with imatinib or GNF-5 inhibited the OVA-induced increase in PCNA staining from
BALB/c mice (n = 6–7, *P < 0.05). C, control animals.
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Abl-lox mice treated with OVA (Figure 7A and C). More-
over, treatment with the Abl inhibitors imatinib or GNF-5
diminished the fluorescent intensity of PCNA in BALB/c
mice treated with OVA (Figure 7C). These results indicate
that Abl has a role in the allergen-induced airway smooth
muscle proliferation.
Effects of conditional knockout of Abl and Abl inhibitors
on airway inflammation in the animal model of asthma
As a consequence of allergic sensitization and chal-
lenge, inflammatory cells enter into the lungs and
cytokine/chemokine levels are increased in the bron-
choalveolar space of asthmatic patients and animalmodels, which are characteristic features of allergic
airway inflammation [7,28,29]. To determine whether the
smooth muscle-specific depletion of Abl affects recruit-
ment of inflammatory cells, we determined total and
differential cell counts of BALF in lungs of naïve and
OVA-treated Abl-lox mice and Ablsm−/− mice.
OVA sensitization and challenge increased the num-
bers of total and differential cells in the lungs of Abl-lox
mice. However, the allergen-induced increase in cell
numbers in the lungs in Ablsm−/− mice was similar to
that in Abl-lox mice (Figure 8A and B).
We also evaluated the effects of the Abl inhibitors
imatinib and GNF-5 on cell counts of BALF from mice
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Figure 8 Effects of Abl knockout, imatinib and GNF-5 on total and differential cell counts in BALF. Total (A) and differential (B) cell
numbers in BALF of Ablsm−/− mice were similar to those of Abl-lox mice when treated with PBS or OVA (n = 6–7). However, treatment with
imatinib or GNF-5 inhibited the OVA-induced increase in total (C) and differential (D) cell numbers in BALF of BALB/c mice (n = 7, *P < 0.05).
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BALF from BALB/c mice. Treatment with imatinib and
GNF-5 reduced the OVA-induced increase in inflamma-
tory cell numbers (Figure 8C and D).
To determine the role of Abl in smooth muscle in the
production of cytokine and chemokine, we evaluated the
level of IL-13 and CCL2 (representative cytokine and
chemokine in asthma pathology) [5,30,31] in the BALF
in lungs of naïve and OVA-treated Abl-lox and Ablsm−/−
mice. OVA sensitization and challenge increased the
level of IL-13 and CCL2 in the BALF of Abl-lox mice. In
addition, the allergen-induced increase in IL-13 and
CCL2 in the lungs of Ablsm−/− mice was similar to those
in Abl-lox mice (Figure 9A and B). However, treatment
with imatinib and GNF-5 diminished the OVA-induced
increase in IL-13 and CCL2 in the lungs of BALB/c mice
(Figure 9C and D).
Discussion
Abl is a non-receptor tyrosine kinase that has a role in
regulating smooth muscle contraction and smooth
muscle cell proliferation in vitro. The role of Abl in the
pathogenesis of asthma in vivo is largely unknown. In
this study, Abl expression is upregulated in asthmatic
airways. More importantly, conditional knockout of Abl
in smooth muscle inhibits airway resistance and airway
smooth muscle growth in the animal model of chronicasthma. The results suggest that Abl plays a critical role
in the progression of AHR and airway remodeling in
chronic asthma.
Our previous studies demonstrate that Abl is essential
for vascular smooth muscle force development [10-13].
In this report, conditional knockout of Abl in smooth
muscle diminished contractile response of tracheal rings.
Moreover, acute inhibition of Abl by the pharmaco-
logical agents attenuated contraction in tracheal rings.
The results suggest that Abl is necessary for airway
smooth muscle contraction. Abl may regulate the func-
tional states of several proteins including Crk-associated
substrate and Abi1, which in turn regulate actin dynam-
ics and smooth muscle contraction [11-13,32,33].
AHR largely stems from hyperreactivity of airway
smooth muscle [1]. The pathological mechanisms that
mediate airway smooth muscle hyperreactivity and AHR
in asthma are not completely elucidated. Th2 cytokines
including IL-13 has been implicated in smooth muscle
hypercontractility and AHR [34-36]. In this study, the
expression of Abl was upregulated in airway tissues of
the animal model of asthma as well as in smooth muscle
cells of patients with severe asthma. Furthermore, condi-
tional knockout of Abl in smooth muscle attenuated air-
way smooth muscle hyperreactivity in vitro and airway
resistance in mice sensitized and challenged by the aller-










































































Figure 9 Effects of Abl knockout, imatinib and GNF-5 on the levels of IL-13 and CCL2 in BALF. (A) The level of IL-13 in BALF of Ablsm−/−
mice was similar to those of Abl-lox mice treated with PBS or OVA (n = 7). (B) Abl conditional knockout did not affect the concentration of CCL2
in BALF (n = 6). (C) The OVA-induced increase in IL-13 level in BALF from BALB/c mice was attenuated by treatment with imatinib or GNF-5
(n= 7, *P < 0.05). (D) Treatment with imatinib or GNF-5 inhibited the OVA-induced enhancement of CCL2 in BALF from BALB/c mice
(n = 6, *P < 0.05).
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effects of the Abl pharmacological inhibitors imatinib
[11,23] and GNF-5 [24] on airway resistance in vivo and
airway smooth muscle hyperreactivity in vitro. Treatment
with the inhibitors also diminished the OVA-sensitized
airway resistance in vivo and tracheal contraction in vitro.
The results suggest that Abl has a critical role in the devel-
opment of AHR in asthma.
Airway remodeling is a characteristic feature of severe
asthma. In addition to fibrosis, enhanced deposition of
extracellular matrix protein, epithelial injury and airway
smooth muscle hypertrophy, proliferation of airway smooth
muscle cells markedly contributes to the pathogenesis of
airway remodeling [6,8,29,37]. Our recent studies demon-
strate that Abl is required for smooth muscle cell proli-
feration in in vitro studies [14,15]. Abl may modulate cell
proliferation by affecting actin polymerization and the
Raf-1/MEK/ERK1/2 pathway [14,15].
Growth factors such as epidermal growth factor and
platelet-derived growth factor have been implicated in
the progression of airway remodeling [7]. In this report,
smooth muscle mass in the airways was reduced in
conditional knockout mice sensitized and challenged by
ovalbumin. In addition, the cell proliferation marker
PCNA was also diminished in conditional knockoutmice treated with the allergen. Moreover, treatment with
the pharmacological inhibitors had similar effects. Thus,
the increased expression of Abl in smooth muscle may
contribute to the development of airway remodeling in
chronic asthma.
In response to allergic sensitization and challenge,
inflammatory cells enter into the lungs and cytokine/
chemokine levels are increased in the bronchoalveolar
space of asthmatic patients and animal models [4,30,34].
Because airway smooth muscle cells have ability to
secret cytokines in vitro [28], we assessed whether Abl
knockout in smooth muscle affects airway inflammation.
Conditional knockout of Abl did not affect the increase
in inflammatory cell numbers, IL-13 and CCL2 in ani-
mals sensitized and challenged by the allergen. The re-
sults lead us to suggest that Abl expression in smooth
muscle does not modulate inflammatory cell infiltration
and production of IL-13 and CCL2 in asthma.
On the contrary, treatment with imatinib and GNF-5
reduced the OVA-induced increase in inflammatory cell
numbers, and levels of IL-13 and CCL2. The results
suggest that global inhibition of Abl diminishes airway
inflammation in chronic asthma, which is consistent
with the findings that Abl may regulate migration and
synthetic functions of immune cells in vitro [38-41].
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β2 agonists reduce symptoms of airway obstruction by
inducing airway smooth muscle relaxation. However, this
therapy has various limitations including β2 adrenergic
receptor desensitization [42]. In this study, we demon-
strate that Abl in smooth muscle has a critical role in
the pathogenesis of AHR and airway remodeling. Fur-
thermore, global inhibition of Abl by pharmacological
agents attenuates airway inflammation. Thus, our fin-
dings support the concept that Abl may be a novel target
for the development of new therapy to treat asthma.
Conclusions
Abl is a non-receptor tyrosine kinase that has a role
in regulating smooth muscle contraction and smooth
muscle cell proliferation in vitro. The role of Abl in
asthma pathogenesis in vivo is not well elucidated. Our
present results suggest that the altered expression of Abl
in smooth muscle plays a critical role in the progression
of AHR and airway remodeling in chronic asthma. Fur-
thermore, global inhibition of Abl attenuates airway in-
flammation. Thus, Abl may be a novel target for the
development of new therapy to treat asthma.
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